Skip to content
Agree.net – Lifestyle
Author:
Zealand Pharma
Zealand Pharma announces Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
April 28, 2026
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
April 22, 2026
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
April 19, 2026
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026
April 19, 2026
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations
April 14, 2026
←
Previous Page
1
…
4
5
6